sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks SU14813

SU14813

CAS No.:
627908-92-3
Catalog Number:
AG00ECER
Molecular Formula:
C23H27FN4O4
Molecular Weight:
442.4833
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%
1 week
United States
$173
- +
10mg
98%
1 week
United States
$215
- +
50mg
98%
1 week
United States
$490
- +
Product Description
Catalog Number:
AG00ECER
Chemical Name:
SU14813
CAS Number:
627908-92-3
Molecular Formula:
C23H27FN4O4
Molecular Weight:
442.4833
MDL Number:
MFCD16495822
IUPAC Name:
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide
InChI:
InChI=1S/C23H27FN4O4/c1-13-20(10-18-17-9-15(24)3-4-19(17)27-22(18)30)26-14(2)21(13)23(31)25-11-16(29)12-28-5-7-32-8-6-28/h3-4,9-10,16,26,29H,5-8,11-12H2,1-2H3,(H,25,31)(H,27,30)/b18-10-
InChI Key:
CTNPALGJUAXMMC-ZDLGFXPLSA-N
SMILES:
OC(CN1CCOCC1)CNC(=O)c1c(C)[nH]c(c1C)/C=C/1\C(=O)Nc2c1cc(F)cc2
Properties
Complexity:
729  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1  
Exact Mass:
442.202g/mol
Formal Charge:
0
Heavy Atom Count:
32  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
4  
Isotope Atom Count:
0
Molecular Weight:
442.491g/mol
Monoisotopic Mass:
442.202g/mol
Rotatable Bond Count:
6  
Topological Polar Surface Area:
107A^2
Undefined Atom Stereocenter Count:
1  
Undefined Bond Stereocenter Count:
0
XLogP3:
0.9  
Literature
Title Journal
Phase I trial of SU14813 in patients with advanced solid malignancies. Annals of oncology : official journal of the European Society for Medical Oncology 20110101
Evaluation of CXCR4 inhibition in the prevention and intervention model of laser-induced choroidal neovascularization. Investigative ophthalmology & visual science 20100701
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 20070915
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Molecular cancer therapeutics 20060701
Properties